OncoTargets and Therapy (Sep 2019)
BCOR mutation and TLS-ERG expression in acute myeloid leukemia with monoclonal immunoglobulinemia
Abstract
Jingxia Jin, Shuna Luo, XingNong Ye, Jian HuangDepartment of Hematology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, People’s Republic of ChinaCorrespondence: Jian HuangDepartment of Hematology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu, Zhejiang 322000, People’s Republic of ChinaTel +86 1 886 796 1032Fax +86 5 798 993 5555Email [email protected]: Acute myeloid leukemia (AML) originates from the abnormal clonal proliferation of myeloblasts. Immunoglobulin is secreted by B cells. AML with monoclonal antibody often indicates a poor prognosis. Here we report a case of BCOR mutation and TLS-ERG expression in AML with monoclonal immunoglobulinemia. After chemotherapy, the patient achieved bone marrow complete remission. BCOR mutation and TLS-ERG fusion gene in patient’s bone marrow were not detected, at the same time, peripheral blood monoclonal immunoglobulin also disappeared. BCOR mutation or TLS-ERG fusion gene expression is associated with poor prognosis, AML with monoclonal immunoglobulin may have the same prognostic significance.Keywords: acute myeloid leukemia, bone marrow, monoclonal immunoglobulin, TLS-ERG, BCOR
